| [1] |
中华医学会风湿病学分会．骨关节炎诊断及治疗指南[J]．中华风湿病学杂志，2010，14(6):416-419.
|
| [2] |
李宁华，张耀南，张毅，等．国内六大行政区域六城市中老年人群膝关节骨性关节炎患病危险因素比较[J]．中国组织工程研究与临床康复，2007，11(39):7758-7760.
|
| [3] |
Tang X, Wang S, Zhang Y, et al. The prevalence of symptomatic knee osteoarthritis in china: Results from china health and retirement longitudinal study [J]. Arthritis Rheumatol, 2016, 68(3): 648-653.
|
| [4] |
Deshpande BR, Katz JN, Solomon DH, et al. The number of persons with symptomatic knee osteoarthritis in the United States：Impact of race/ethnicity, age, sex, and obesity[J]. Arthritis Care Res (Hoboken), 2016, 68(12): 1743-1750.
|
| [5] |
Yildiz N, Topuz O, Gungen GO, et al. Health-related quality of Life (Nottingham Health Profile) in knee osteoarthritis: correlation with clinical variables and self-reported disability[J]. Rheumatol Int, 2010, 30(12): 1595-1600.
|
| [6] |
张金山，刘健，杨佳，等.60例膝骨关节炎患者生活质量变化及其相关性分析[J]．中医药临床杂志，2011，23(6):528-530.
|
| [7] |
朱才兴，郭燕梅，陈蔚，等．老年膝骨关节炎患者生活质量影响因素分析[J]．中国康复理论与实践，2011，17(11):1052-1055.
|
| [8] |
Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham study[J]. Am J Public Health, 1994, 84(3): 351-358.
|
| [9] |
Mcalindon T, Cooper C, Kirwan J, et al. Determinants of disability in osteoarthritis of the knee[J]. Ann Rheum Dis, 1993, 52(4): 258-262.
|
| [10] |
Kaplan W, Cesar J. Background Paper 5-Demography, global burden of disease and the preliminary list of priorities. Priority Medicines for Europe and the World 2013 Update, Groningen, 2013. World Health Organization.
URL
|
| [11] |
史方，顾凯，卢伟，等．上海市关节炎疾病经济负担评价[J]．中国卫生资源，2007，10(2):92-94.
|
| [12] |
Woo J, Lau E, Lau CS, et al. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs[J]. Arthritis Rheum, 2003, 49(4): 526-534.
|
| [13] |
Leardini G, Salaffi F, Caporali R, et al. Direct and indirect costs of osteoarthritis of the knee[J]. Clin Exp Rheumatol, 2004, 22(6): 699-706.
|
| [14] |
卢亮宇，王予彬．膝骨关节炎疼痛机制及治疗研究现状[J]．中国运动医学杂志，2007，26(4):512-516.
|
| [15] |
Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade iv osteoarthritis[J]. J Manag Care Pharm, 2007, 13(2): 113-121.
|
| [16] |
Balazs EA, Watson D, Duff IF, et al. Hyaluronic acid in synovial fluid.I .molecular parameters of hyaluronic acid in normal and arthritic human fluids[J]. Arthritis Rheum, 1967, 10(4): 357-376.
|
| [17] |
Balazs E. The physical properties of synovial fluid and the special role of hyaluronic acid [M]. In: Helfet, A．J. Ed. Disorders of the Knee. Philadelphia: JB Lippincott, 61-74.
|
| [18] |
Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with Hylan G-F 20 (synvisc®)in the treatment of osteoarthritis of the knee：a Canadian multicenter trial comparing Hylan G-F 20 alone, Hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDS) and NSAIDS alone[J]. Osteoarthritis Cartilage, 1995, 3(4): 213-225.
|
| [19] |
Caborn D, Rush J, Lanzer W, et al. A randomized, single-blind comparison of the efficacy and tolerability of Hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee[J]. J Rheumatol, 2004, 31(2): 333-343.
|
| [20] |
Raman R, Dutta A, Day N, et al. Efficacy of Hylan GF 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee-a prospective randomized clinical trial[J]. Knee, 2008, 15(4): 318-324.
|
| [21] |
Raynauld JP, Torrance G, Band P, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of Hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis(part 1 of 2)：Clinical results[J]. Osteoarthritis Cartilage, 2002, 10(7): 506-517.
|
| [22] |
Khanasuk Y, Dechmaneenin T, Tanavalee A. Prospective randomized trial comparing the efficacy of single 6 ml injection of Hylan G-F 20 and hyaluronic acid for primary knee arthritis: a preliminary study[J]. J Med Assoc Thai, 2012, 95(Suppl 10): S92-S97.
|
| [23] |
Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medicoeconomic benefits of Hylan G-F 20 vs.conventional treatment in knee osteoarthritis[J]. Joint Bone Spine, 2003, 70(4): 276-281.
|
| [24] |
Torrance G, Raynauld J, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of Hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis(part 2 of 2)：Economic results[J]. Osteoarthritis Cartilage, 2002, 10(7): 518-527.
|
| [25] |
Waddell D, Rein A, Panarites C, et al. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting[J]. Am J Manag Care, 2001, 7(10): 981-991
|
| [26] |
Kostyuk A, Almadiyeva A, Akanov A. The effectiveness and cost-effectiveness of Hylan G-F 20 in osteoarthritis of the knee[J]. Value in Health, 2015, 18(7): A647-A647.
|
| [27] |
Chou CW, Lue KH, Lee HS, et al. Hylan GF 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan[J]. J Formos Med Assoc, 2009, 108(8): 663-672.
|
| [28] |
Arnold W, Fullerton DS, Holder SA. Viscosupplementation: managed care issues for osteoarthritis of the knee[J]. J Manag Care Pharm, 2007, 13(4, S): S3-S19.
|
| [29] |
邓峰，吕菊红，高建民，等. "金砖五国"医疗资源与卫生费用比较分析[J]. 中国卫生经济，2014，33(2):94-96.
|